Compare Nuwellis Inc (NUWE) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Nvidia Corp — how do they compare? Nuwellis Inc trades at $2.84 (market cap $1.09M), while Nvidia Corp trades at $206.72 (market cap $4.92T). The key difference: Nvidia Corp is far larger — about 4513761.5× Nuwellis Inc's market cap, and Nvidia Corp pays a 0.49% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| NUWE | NVDA | |
|---|---|---|
Market Cap | $1.09M | $4.92T |
Sector | Technology | Technology |
52-Week High | $527.46 | $235.75 |
52-Week Low | $2.80 | $165.17 |
Enterprise Value | -$722.58K | $4.86T |
Dividend Yield | — | 0.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $3.00, up 5.26% today, following a 35:1 reverse stock split effective June 26, 2026. The company shows a low P/E of 0.06 and P/S of 0.01, but fundamentals are weak with a -217.22% net income margin and negative ROE. Recent news highlights patent awards and pediatric market expansion, yet cash flow remains negative. Analyst coverage is limited with a split buy/hold consensus.
Outlook is speculative; growth depends on successful commercialization of Aquadex therapy and cost management. Key risks include persistent losses, high cash burn, and competitive pressures. Investors should weigh low valuation against execution risks in the medical technology sector.
Nvidia (NVDA) trades at $207.14, up 2.14% today, with a neutral technical signal and strong fundamental performance. Recent earnings consistently beat estimates, with Q1 2026 EPS of $1.87 exceeding the $1.76 forecast. Revenue surged to $130.50B in 2025, driving a net income margin of 62.97%. The stock faces resistance near $210, while support holds at $201.
Outlook remains positive due to AI-driven growth and robust profitability, but risks include peak AI spending concerns and competitive pressures. Analysts project a $325.86 price target, with 75% recommending Buy. Investors should weigh high valuation multiples against sustained earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
